ABSTRACT

Introduction

Biologic agents have revolutionized the therapeutic management of ulcerative colitis. Anti-tumor necrosis factor agents were the first biologic drugs used to induce and maintain remission in this inflammatory bowel disease. Recently, another biologic option, ustekinumab, has become available for the treatment of moderate-to-severe ulcerative colitis.

Areas covered

In this article, the authors review the literature on the efficacy and safety of ustekinumab in the context of current biologic agents used for the management of this disease. The potential role of ustekinumab in the treatment paradigm of the disease is also discussed.

Expert opinion: The UNIFI trial has demonstrated the efficacy and safety of ustekinumab in induction and maintenance phases of treatment for ulcerative colitis. Ustekinumab may provide clinical benefit in a range of settings in patients with ulcerative colitis, even for those with multiple treatment failures, which are relatively common in daily clinical practice. Future clinical trials should compare the efficacy of ustekinumab with existing biologic agents in the management of ulcerative colitis.

中文翻译：

---

Ustekinumab治疗溃疡性结肠炎的专家意见。

摘要

介绍

生物制剂彻底改变了溃疡性结肠炎的治疗方法。抗肿瘤坏死因子药物是用于诱导和维持这种炎性肠病缓解的首批生物药物。最近，另一种生物学选择ustekinumab已可用于治疗中度至重度溃疡性结肠炎。

覆盖区域

在本文中，作者们回顾了乌斯替单抗在当前用于治疗该病的生物制剂中的功效和安全性的文献。还讨论了ustekinumab在该疾病治疗范例中的潜在作用。

专家意见：UNIFI试验已证明ustekinumab在溃疡性结肠炎的诱导和维持阶段的疗效和安全性。Ustekinumab可能在溃疡性结肠炎患者的各种情况下提供临床益处，即使对于那些治疗失败的患者（在日常临床实践中相对较常见）也是如此。未来的临床试验应比较乌斯替单抗与现有生物制剂在溃疡性结肠炎治疗中的功效。